Prosecution Insights
Last updated: April 19, 2026

Hanmi Pharm. Co., Ltd.

23 pending office actions

Portfolio Summary

23
Total Pending OAs
9
Final Rejections
14
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18576610 ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN FAY, ZOHREH ALEMZADEH 1617 Non-Final OA Jan 04, 2024
18251827 PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR WEDDINGTON, KEVIN E 1629 Non-Final OA Dec 12, 2023
18549622 BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS CHONG, YONG SOO 1623 Non-Final OA Sep 08, 2023
18036538 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE JONES-FOSTER, ERICA NICOLE 1656 Non-Final OA May 11, 2023
18036580 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE JONES-FOSTER, ERICA NICOLE 1656 Non-Final OA May 11, 2023
18031940 PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES LANDSMAN, ROBERT S 1647 Non-Final OA Apr 14, 2023
18032076 PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS KATAKAM, SUDHAKAR 1658 Final Rejection Apr 14, 2023
18028420 THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF HUYNH, PHUONG N 1641 Non-Final OA Mar 24, 2023
18028424 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES, COMPRISING TRIPLE AGONIST OR CONJUGATE THEREOF HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1 AND GLP RECEPTORS XIE, XIAOZHEN 1674 Non-Final OA Mar 24, 2023
18040869 PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST CHANDRA, GYAN 1674 Final Rejection Feb 07, 2023
18016165 THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE ROSSI, JULIA ANNE LORRAIN 1615 Final Rejection Jan 13, 2023
18016145 THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST CHANDRA, GYAN 1674 Non-Final OA Jan 13, 2023
17927150 LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE CHANDRA, GYAN 1674 Non-Final OA Nov 22, 2022
17927257 LIQUID FORMULATION CARTER, SANDRA DILLAHUNT 1674 Non-Final OA Nov 22, 2022
17926912 LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST ROSSI, JULIA ANNE LORRAIN 1615 Final Rejection Nov 21, 2022
17915976 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME BRADLEY, CHRISTINA 1654 Non-Final OA Sep 29, 2022
17880358 IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN DAHLE, CHUN WU 1641 Final Rejection Aug 03, 2022
17788488 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF SABILA, MERCY HELLEN 1654 Non-Final OA Jun 23, 2022
17839053 METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE REYNOLDS, FRED H 1658 Final Rejection Jun 13, 2022
17766137 COMPOSITION COMPRISING GLUCAGON AND GLP-1 AND GIP RECEPTOR DUAL AGONIST AND THERAPEUTIC USE OF SAME HELLMAN, KRISTINA M 1654 Final Rejection Apr 01, 2022
17700055 TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST FISCHER, JOSEPH 1658 Non-Final OA Mar 21, 2022
17416880 A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST SABILA, MERCY HELLEN 1654 Final Rejection Jun 21, 2021
17282661 THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME KONOPELSKI SNAVEL, SARA ELIZABETH 1658 Final Rejection Apr 02, 2021

Managing Hanmi Pharm. Co., Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month